Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B.
Targeting of tumor tissues is one of the most powerful approaches to accelerate the efficiency of anticancer treatments. The investigation of effective targets, including proteins specifically and abundantly expressed in abnormal regions, has been one of the most important research topics in cancer therapy. In this study, we performed a proteomic analysis on human breast carcinoma tissues to investigate the tumor-specific protein expression in breast carcinoma. Our study showed that ATP synthase was up-regulated in tumor tissues and was present on the plasma membrane of breast cancer cells. Furthermore, we treated the breast cancer cells with ATP synthase inhibitors and examined the inhibitory efficiency. Aurovertin B, an ATP synthase inhibitor, has strong inhibition on the proliferation of several breast cancer cell lines, but little influence on the normal cell line MCF-10A. Aurovertin B inhibits proliferation of breast cancer cells by inducing apoptosis and arresting cell cycle at the G0/G1 phase. This study showed aurovertin B can be used as an antitumorigenic agent and may be exploited in cancer chemotherapy.
Huang
Tsui-Chin
TC
Institute of Molecular and Cellular Biology, National Taiwan University, Taipei 106, Taiwan.
Chang
Hsin-Yi
HY
Hsu
Chun-Hua
CH
Kuo
Wen-Hung
WH
Chang
King-Jen
KJ
Juan
Hsueh-Fen
HF
D017209:Apoptosis / Q000187:drug effects; D001313:Aurovertins / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D008565:Membrane Proteins / Q000032:analysis / Q000378:metabolism; D025261:Mitochondrial Proton-Translocating ATPases / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008958:Models, Molecular; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
C506526:ATP5F1B protein, human; D001313:Aurovertins; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D013267:Stilbenes; C034402:aurovertin B; C041525:3,3',4,5'-tetrahydroxystilbene; D025261:Mitochondrial Proton-Translocating ATPases; D000077185:Resveratrol